Watch and wait

Buysiders’ dim views of the big caps heading into 2018

Heading into 2018, buysiders expressed more concerns than optimism about former darlings in the large cap tier.

WBB Securities’ John Nolan, ClearBridge Investments’ Marshall Gordon and AXA Investment Managers’ Linden Thomson are following patent litigation and cardiovascular outcomes data for hypercholesterolemia drug Praluent alirocumab from Regeneron Pharmaceuticals Inc. and Sanofi, but they remain pessimistic on the PCSK9 inhibitor’s commercial prospects.

“While I would like to think outcomes data will help Praluent, I’m not that hopeful that payers will change their restrictions,” said Gordon. “The damage is already done.” The CVOT data are expected this quarter.

In addition,

Read the full 948 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE